Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.35 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.35 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921427 | 0.85 | JAK2 (0.43) | JAK2USP30KDM4EPOLBMAPT | |
| SCHEMBL13841080 | 0.80 | JAK2 (0.66) | JAK2CCNE1CDK2 | |
| SCHEMBL3926096 | 0.80 | MAPK8 (0.45) | JAK2USP30KDM4EPOLBMAPT | |
| SCHEMBL3922888 | 0.79 | JAK2 (0.43) | JAK2KDM4EPOLBMAPTTDP1 | |
| SCHEMBL3924285 | 0.79 | JAK2 (0.44) | JAK2KDM4EPOLBMAPTTDP1 | |
| SCHEMBL3932781 | 0.78 | NUDT1 (0.46) | JAK2USP30KDM4EPOLBMAPT | |
| SCHEMBL3923459 | 0.78 | JAK2 (0.44) | JAK2KDM4EPOLBMAPTTDP1 | |
| SCHEMBL3926065 | 0.78 | PIK3CB (0.36) | KDM4EPOLBMAPTTDP1ALDH1A1 | |
| SCHEMBL3926142 | 0.77 | NUDT1 (0.41) | JAK2KDM4EPOLBMAPTTDP1 | |
| SCHEMBL3921271 | 0.77 | NUDT1 (0.55) | JAK2USP30KDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051980-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | JAK2 1/4885USP30 2950/4885KDM4E 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.